Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

Quick summary of IPCI as follows:

IPCI's O/S is 31M

IPCI has 9 proprietary control release and abuse deterrence delivery tech platforms.

IPCI has 10 ANDA's filed with the FDA.

4 of their ANDA's have been FDA approved so far.

2 of their ANDA's have been fully commercialized so far(PAR/FocalinXR and MNK/SeroquelXR)

2 still to be FDA approved ANDA's are already partnered with MNK(Pristiq & Lamictal)

IPCI has also filed 2 NDA's with the FDA(1 for OxyContin which IPCI originally called Rexista & 1 for Lyrica which IPCI has named as Regabatin)

IPCI is currently working on completing and submitting oral and nasal HAP studies on their OxyContin NDA candidate formerly known as Rexista. We're still waiting for confirmation from IPCI mgmt. as to whether those studies have been started yet. The studies will take approximately 9 months to complete, then IPCI can submit those studies to the FDA and get another AdCom scheduled and PDUFA date granted by the FDA. Purdue's patent on OxyContin expires in the summer of 2019 so the still outstanding lawsuit that Purdue launched against IPCI when IPCI filed their OxyContin NDA candidate with the FDA will most likely get wrapped up by the end of this year if IPCI mgmt. does in fact complete the oral and nasal studies this year.

IPCI was granted a fast track designation from the FDA and a patent from the USPTO on PODRAS...then mgmt. stated last year that they were going to be doing studies on their PODRAS(Overdose Prevention) proprietary delivery tech platform. But as of right now, we're still waiting for a full status/progress update on PODRAS so we know what stage their actually at. PODRAS is going to take 2 full years worth of extensive R&D/clinical and human trials, and cost somewhere north of $20M to complete. So IPCI securing a Research and Development partner on PODRAS should become of paramount importance the moment IPCI mgmt. informs the market on the status of the 1st studies IPCI previously telegraphed they were to start sometime in the back half of 2017.

IPCI and its founders(Dr Odidi and wife) have filed numerous patent applications and have already been granted numerous patents pertaining to their control release delivery technologies. So if they can somehow start finding a way to truly begin unlocking some of the potential inherent value in the delivery technologies pertaining to their NDA's, sometime by/b4 EOY 2018...IPCI should begin to get viewed in a more positive manner.

More info on all of the above contained in the ibox glta